Previous 10 | Next 10 |
Passage Bio press release (NASDAQ:PASG): Q4 GAAP EPS of -$0.95 misses by $0.06. Q4 cash equivalents $315.8M For further details see: Passage Bio GAAP EPS of -$0.95 misses by $0.06
Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosis Dosed first patients in Cohorts 2 (late infantile, high dose) and 3 (early infantile, low dose) i...
PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m....
The following slide deck was published by Passage Bio, Inc. in conjunction with this event. For further details see: Passage Bio (PASG) Presents At 2022 WORLD Symposium Data Conference
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregivers Interim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with...
The following slide deck was published by Passage Bio, Inc. in conjunction with this event. For further details see: Passage Bio (PASG) Presents At J.P. Morgan 40th Annual Healthcare Conference
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11 Podium presentations on clinical trial designs for Imagine-1 and GALax-C, the clinical trial for Krabbe disease, Wednesday, February 9 G...
Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the 18 th Annual WORLD Symposium, February 11, 2022 Dose first patients in Cohorts 2 and 3 in GM1 gangliosidosis clinical trial in early 2022 ...
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Bruce Goldsmith, Ph.D., president, and chief executive...
– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious adverse events, no complications related to intra-cisterna magna inj...
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...